Schweizerisches Register für TNF-alpha-Blocker bei Kindern und Jugendlichen mit rheumatologischen Erkrankungen [Swiss registry for TNF-alpha blockers in children and adolescents with rheumatological diseases].
| Data(s) |
2010
|
|---|---|
| Resumo |
We created a registry to evaluate long term outcome, efficacy and adverse events for children treated wit TNF-alpha inhibitors in Switzerland. 106 patients (68 female/38 male) were included. 61 patients were treated with Etanercept (Enbrel) and 45 with Infliximab (Remicade). Concomitant treatment at baseline included corticosteroids in 26% and Methotrexate in 75% of the patients. Subjective disease activity three months after initiation of TNF-alpha was better in 81%, worse in 4% and stable in 15% of the patients. In total 24 adverse events in 21 patients were reported. Treatment with TNF-alpha inhibitors seems to be safe and effective for children and adolescents with rheumatologic diseases. |
| Identificador |
http://serval.unil.ch/?id=serval:BIB_AF850DE04014 isbn:1661-8157 (Print) pmid:20506089 doi:10.1024/1661-8157/a000144 |
| Idioma(s) |
de |
| Fonte |
Praxis, vol. 99, no. 11, pp. 649-654 |
| Palavras-Chave | #Adolescent; Adverse Drug Reaction Reporting Systems; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal/therapeutic use; Antirheumatic Agents/adverse effects; Antirheumatic Agents/therapeutic use; Arthritis, Juvenile Rheumatoid/drug therapy; Child; Drug Interactions; Drug Therapy, Combination; Humans; Immunoglobulin G/adverse effects; Immunoglobulin G/therapeutic use; Product Surveillance, Postmarketing; Receptors, Tumor Necrosis Factor/therapeutic use; Registries; Rheumatic Diseases/drug therapy; Switzerland; Treatment Outcome; Tumor Necrosis Factor-alpha/antagonists & inhibitors; Uveitis/drug therapy |
| Tipo |
info:eu-repo/semantics/article article |
